Developments in survival and treatment of multiple myeloma patients with soft tissue plasmocytoma - A retrospective analysis of 130 patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00035121

Enrollment

130

Registered

2024-09-25

Start date

2022-10-22

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma and primary or secondary soft tissue plasmocytoma

Interventions

Group 1: All patients of age >18 years of the Department of Internal Medicine III at Klinikum Chemnitz gGmbH with diagnosed Multiple Myeloma and primary or secondary soft tissue plasmocytoma between 2

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosed Multiple Myeloma and primary or secondary soft tissue plasmocytoma

Exclusion criteria

Exclusion criteria: Exclusion criteria are not required due to the retrospective study design

Design outcomes

Primary

Measure	Time frame
Primary endpoint of the trial was the evaluation of progression free survival (PFS, time from soft tissue plasmocytoma diagnosis until progression) and overall survival (OS) dependent on patient characteristics and treatment procedures.	—

Secondary

Measure	Time frame
Assessment of overall response ratio (ORR). This was based on IMWG criteria.	—

Countries

Germany

Contacts

Public ContactMathias Hänel

Klinikum Chemnitz gGmbH

m.haenel@skc.de+49 371 333 44501

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026